A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

Biochem Biophys Res Commun. 1990 Dec 14;173(2):534-40. doi: 10.1016/s0006-291x(05)80067-1.


LNCaP prostate tumor cells contain an abnormal androgen receptor system. Progestagens, estradiol and anti-androgens can compete with androgens for binding to the androgen receptor and can stimulate both cell growth and excretion of prostate specific acid phosphatase. We have discovered in the LNCaP androgen receptor a single point mutation changing the sense of codon 868 (Thr to Ala) in the ligand binding domain. Expression vectors containing the normal or mutated androgen receptor sequence were transfected into COS or Hela cells. Androgens, progestagens, estrogens and anti-androgens bind the mutated androgen receptor protein and activate the expression of an androgen-regulated reporter gene construct (GRE-tk-CAT). The mutation therefore influences both binding and the induction of gene expression by different steroids and antisteroids.

MeSH terms

  • Binding Sites
  • Binding, Competitive
  • Gene Expression Regulation, Neoplastic
  • HeLa Cells
  • Humans
  • Ligands*
  • Male
  • Mutation
  • Prostatic Neoplasms / genetics*
  • Receptors, Androgen / genetics*
  • Receptors, Androgen / immunology
  • Steroids / immunology
  • Steroids / metabolism*
  • Transfection
  • Tumor Cells, Cultured


  • Ligands
  • Receptors, Androgen
  • Steroids